DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Linear nevus sebaceus syndrome — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLinear nevus sebaceus syndrome maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for linear nevus sebaceus syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Two case reports from 1973 describe patients with linear nevus sebaceus syndrome; one had retardation, seizures, and classic ectodermal lesions, the other had cutaneous lesions and only an elevated cerebrospinal fluid protein as neurologic evidence. A 2010 report describes a child with a large congenital scalp nevus excised in three stages during the second year of life, who later developed delayed milestones and seizures, leading to a diagnosis of linear nevus sebaceous syndrome (LNSS), a subtype of epidermal nevi associated with seizures, psychomotor retardation and neurocognitive delays. A 2023 case report of a Bangladeshi child notes that up to 30% of sebaceous nevi are associated with syndromic conditions, and that after cutaneous manifestation, central nervous system and ocular anomalies are common in almost every case.
A 2003 surgical series of five patients treated over ten years describes excision and reconstruction of giant sebaceous nevi of the face and scalp in children with LNSS; the authors state this is the largest surgical series and suggests a reliable approach to treating the cutaneous manifestations. The 2010 report emphasises that paediatricians should be aware of the spectrum of epidermal nevus syndromes and make timely treatment referrals. The 2023 report states that adequate knowledge and a high degree of suspicion can identify this rare disease and minimise unwanted morbidity.
No drug treatments are mentioned in any of these abstracts. No data on survival, response rates, or drug efficacy are reported. The literature consists entirely of case reports and a small surgical series, with no controlled trials, no randomised comparisons, and no evidence for any pharmacological intervention. What is missing is any clinical trial of a drug, any systematic study of medical therapy, any patient stratification by genetic mutation, and any funding for such research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 1973 · 78 citations
LINEAR NEVUS SEBACEOUS SYNDROME: REPORT OF TWO CASES AND A REVIEW OF THE LITERATURE
AbstractTwo cases of linear nevus sebaceous syndrome are described and a review of the eleven cases now reported in the literature is undertaken. The first patient has retardation, seizures, and classic ectodermal lesions while the second patient manifests typical cutaneous lesions and only an elevated cerebrospinal fluid protein as evidence of neurologic disease. The rationale for defining the syndrome as an entity distinct from other neurocutaneous syndromes is discussed and a pleomorphic presentation of the syndrome is suggested.
Plastic & Reconstructive Surgery · 2003 · 26 citations
Surgical Management of the Cutaneous Manifestations of Linear Nevus Sebaceus Syndrome
AbstractLinear nevus sebaceus syndrome is characterized by the association of nevus sebaceus covering extensive areas on the head and scalp with abnormalities of the central nervous system, ophthalmologic and skeletal changes, and malignancies. The incidence is approximately one per 10,000 live births, and there is no sexual predilection reported. The original description of this syndrome was followed by extensive literature describing the dermatologic, neurologic, and ophthalmologic manifestations of this disease. The objective of this report is to describe the surgical approach for the excision and reconstruction of giant sebaceous nevi of the face and scalp in children with linear nevus sebaceus syndrome on the basis of a consecutive series of five patients treated over 10 years in the same institution. To the authors' knowledge, this report represents the largest surgical series and suggests a reliable approach to the treatment of the cutaneous manifestations of this syndrome.
A child with a congenital epidermal nevus, epilepsy and developmental delays: Linear nevus sebaceous syndrome
AbstractAbstractThis report describes a child who presented at birth with a large congenital scalp nevus that was successfully serially excised in three stages during the second year of life. As the child's development progressed, delayed milestones became apparent and seizures developed. The child was diagnosed with linear nevus sebaceous syndrome (LNSS). LNSS is a subtype of epidermal nevi associated with seizures, psychomotor retardation and neurocognitive delays. It is essential for pediatricians to be aware of the existence of a spectrum of epidermal nevus syndromes and make timely treatment referrals.
BOHR International Journal of Current Research in Optometry and Ophthalmology · 2023 · 0 citations · open access
Linear nevus sebaceous syndrome with bilateral ocular involvement in a Bangladeshi child: A case report with literature review
AbstractThe linear sebaceous nevus is one of a variety of epidermal nevi, which is a congenital ectodermal hamartoma that occurs due to post-zygotic mosaic mutation. Such sebaceous nevus is one of the commonest nevi, and up to 30% are associated with syndromic associations, which are rare. After cutaneous manifestation, central nervous system and ocular anomalies are common and found in almost every case. Multiorgan involvement can lead to various minor or major morbidities. Adequate knowledge and a high degree of suspicion can identify this rare disease and can minimize unwanted morbidity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
